After preparing the grant applications for 1.5 years, the Hypo-RESOLVE consortium was in great anticipation of the day that would launch the project activities officially. From May 16-17, 2018, the whole group came together in Favrholm, Denmark to outline and discuss planned activities and enter into dialogue with representatives of the Patient and Strategic Advisory Committees. The meeting was hosted by Novo Nordisk, Project Leader of the action. Stephen Gough, Global Chief Medical Officer at Novo Nordisk gave an inspiring opening statement and Project Coordinator Bastiaan de Galan from Radboud university medical center then presented the overall project aims to the audience. As Hypo-RESOLVE is committed to interact closely with people living with diabetes, the Patient Advisors were invited to contribute an opening statement to the 85 participants of the meeting. Renza Scibilia gave personal insights into living with the fear of hypoglycaemia and the effect it has on her daily life.
The first meeting day continued with presentations by the different work package leaders and co-leaders and ended with a nicely organised matchmaking event for the dinner which rounded off the day. On day two of the meeting, the Strategic Advisory Board members gave valuable feedback on the project design and food for thought for the working groups in their thematic break-out sessions. After the scientific discussions had taken place, work package leaders and co-leaders came together with the Patient Advisory Committee once more in order to define where patient insight and closer collaboration could contribute to the successful implementation of the project.
The consortium partners will now take action in their dedicated work packages and reconvene in regular managing board meetings to discuss progress further during the months to come. We are looking forward to an exciting and scientifically inspiring next four years!